Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
*Note that 350 patients were treated in total, however due to the combinations that have been asked for some of these patients have been double counted e.g. a patient may be on “Taxane and/or Anthracycline in combination” and also “Trastuzumab as a single agent or in combination” as part of the combination
|
Treatment
|
No treated
|
|
Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
|
20
|
|
Abemaciclib + Fulvestrant
|
18
|
|
Alpelisib + Fulvestrant
|
0
|
|
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
|
0
|
|
Atezolizumab +Nab-paclitaxel/Paclitaxel
|
< 5
|
|
Capecitabine as a single agent
|
6
|
|
Eribulin as a single agent or in combination
|
< 5
|
|
Everolimus + Exemestane
|
< 5
|
|
Fulvestrant as a single agent
|
6
|
|
Lapatinib
|
0
|
|
Neratinib
|
0
|
|
Parp Inhibitors (Olaparib/Talazoparib)
|
0
|
|
Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
|
37
|
|
Palbociclib + Fulvestrant
|
14
|
|
Pembrolizumab
|
0
|
|
Platinum (e.g. carboplatin or cisplatin) as a single agent
|
0
|
|
Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
|
< 5
|
|
Ribociclib + Fulvestrant
|
0
|
|
Sacituzumab Govitecan
|
5
|
|
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
|
9
|
|
Taxane and/or Anthracycline in combination
|
104
|
|
Trastuzumab as a single agent or in combination
|
85
|
|
Trastuzumab emtansine
|
22
|
|
Transtuzumab deruxtecan
|
< 5
|
|
Any other active systemic anti-cancer therapy
|
18
|
Q2. Does your trust participate in any clinical trials for breast cancer? If so, can you please provide the name of each trial and the number of patients taking part.
Poetic-A PreOperative Endocrine Therapy for Individualised Care with Abemaciclib (9 participants)
EUCHARIS European treatment patterns and outcomes associated with first line CDK and Hormonal therapies Assessed in a Real-world non-Interventional Study (16 participants)
